A meta-analysis of 12 randomized controlled trials involving 1,181 gastric cancer patients demonstrated that hyperthermic intraperitoneal chemotherapy (HIPEC) significantly improved survival rates compared to control groups at 1, 2, 3, and 5 years. The recurrence rates were notably lower in the HIPEC group, and higher disease-free survival rates were also observed. These findings suggest that HIPEC offers promising outcomes for gastric cancer treatment, warranting further multicenter studies with diverse patient populations.
Review by Chen Y, Zhou Y (…) Li S et 3 al. in Ann Surg Oncol
© 2024. Society of Surgical Oncology.